Crown Castle completes $8.4 billion fiber and small cell business sale
Get Alerts CCI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.6%
Revenue Growth %: -7.8%
Join SI Premium – FREE
Crown Castle Inc. (NYSE: CCI) announced the completion of its sale of fiber solutions and small cell businesses to Zayo Group Holdings Inc. and Arium Networks for $8.4 billion net of preliminary adjustments, the company said in a press release statement.
The telecommunications infrastructure company plans to use $1.0 billion of the proceeds for share repurchases under a board-approved program effective May 1, 2026, and reduce outstanding debt by more than $7.0 billion.
Crown Castle updated its full year 2026 outlook following the transaction closure. The company expects site rental revenues between $3.83 billion and $3.87 billion, with net income projected at $690 million to $970 million. Adjusted funds from operations (AFFO) per share is forecast at $4.53 to $4.65.
The sale proceeds were received two months earlier than initially anticipated, resulting in a $40 million decrease in projected interest expense and $10 million increase in interest income compared to the previous outlook issued April 22, 2026.
Interest expense is expected to decrease by approximately $160 million from debt repayment following the business sale closure. The company anticipates repaying debt outstanding on credit facilities and commercial paper programs.
Crown Castle now operates as a pure-play tower company focused on the U.S. market, owning approximately 40,000 cell towers nationwide. The company expects discretionary capital expenditures between $150 million and $250 million for 2026.
The transaction involved EQT Active Core Infrastructure acquiring the small cells business while Zayo acquired the fiber solutions business. The sale represents a strategic shift for Crown Castle to focus exclusively on its tower portfolio.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eldorado Gold elects nine directors at 2026 annual meeting
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
- 8x8 reports data breach via third-party Salesforce integration
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsRelated Entities
Dividend, Stock Buyback, Earnings, Definitive Agreement, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share